Technical Analysis for LQDA - Liquidia Technologies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Volume Surge | Other | 0.33% | |
Oversold Stochastic | Weakness | 0.33% | |
Stochastic Reached Oversold | Weakness | -2.75% | |
Oversold Stochastic | Weakness | -2.75% | |
NR7 | Range Contraction | -2.27% | |
Oversold Stochastic | Weakness | -2.27% | |
180 Bearish Setup | Bearish Swing Setup | -1.95% | |
Stochastic Buy Signal | Bullish | -1.95% |
Alert | Time |
---|---|
Possible Inside Day | about 6 hours ago |
Up 2% | about 10 hours ago |
Down 1% | about 10 hours ago |
Up 1% | about 10 hours ago |
Down 5% | 3 days ago |
Get a Trading Sidekick!
- Earnings date: 08/08/2024
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Clinical Trial Opioids Pulmonary Arterial Hypertension Uniform Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.99 |
52 Week Low | 5.71 |
Average Volume | 815,826 |
200-Day Moving Average | 11.13 |
50-Day Moving Average | 12.85 |
20-Day Moving Average | 13.08 |
10-Day Moving Average | 12.40 |
Average True Range | 0.61 |
RSI (14) | 39.39 |
ADX | 18.76 |
+DI | 13.64 |
-DI | 25.15 |
Chandelier Exit (Long, 3 ATRs) | 13.36 |
Chandelier Exit (Short, 3 ATRs) | 13.56 |
Upper Bollinger Bands | 14.65 |
Lower Bollinger Band | 11.50 |
Percent B (%b) | 0.17 |
BandWidth | 24.11 |
MACD Line | -0.29 |
MACD Signal Line | -0.17 |
MACD Histogram | -0.1181 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.67 | ||||
Resistance 3 (R3) | 12.68 | 12.47 | 12.57 | ||
Resistance 2 (R2) | 12.47 | 12.31 | 12.47 | 12.53 | |
Resistance 1 (R1) | 12.26 | 12.21 | 12.16 | 12.25 | 12.49 |
Pivot Point | 12.05 | 12.05 | 12.00 | 12.05 | 12.05 |
Support 1 (S1) | 11.84 | 11.89 | 11.74 | 11.83 | 11.59 |
Support 2 (S2) | 11.63 | 11.79 | 11.63 | 11.55 | |
Support 3 (S3) | 11.42 | 11.63 | 11.52 | ||
Support 4 (S4) | 11.41 |